Escitalopram Use in Depression & the Influence of Genetic Variations on Its Safety & Efficacy

Clicks: 384
ID: 276395
2022
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1 of 12 articles by views in Precision Medicine Communications

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Major depressive disorder (MDD) is a common debilitating mental illness marked by sad feelings, depressed mood, and lack of interest in routine chores that persists daily or for a minimum of two weeks.  Serotonin-norepinephrine inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and atypical antidepressants are some of the common classes of drugs used for the treatment of MDD. Despite strenuous efforts by the researchers, hardly any new antidepressant agent has entered the market. Escitalopram, a highly selective serotonin reuptake inhibitor, is the drug of choice for the treatment of MDD. However, although escitalopram is one of the most frequently prescribed antidepressant agents, a large percentage of MDD patients show variable remission and response to escitalopram.  Scientists spent decades finding the underlying mechanism responsible for the significant variations in drug response and incidence of adverse effects. These inter-individual variations in therapeutic response serve as a foundation for the inception of the pharmacogenomic. Pharmacogenomics is a field of research that expounds on the impact of gene variation on altered clinical outcomes of drugs. There has been substantial hope and potential that pharmacogenomics will ameliorate the current therapies for MDD and aid in finding novel targets for new drug discoveries. Currently, numerous candidate genes have been identified, implicated in changing drug response, whether at the receptor, transporter, or drug-metabolizing enzyme. In this review, we attempt to compile the studies on the genetic variations that have been found to be associated with escitalopram efficacy and adverse effects and briefly discuss the pathophysiology and currently available treatment options for MDD
Reference Key
Zaheer2022precisionEscitalopram Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tahreem Zaheer;Fatima Shahid;Pratima Chhetri;
Journal Precision Medicine Communications
Year 2022
DOI
146
URL
https://rootspress.org/journals/index.php/PMC/article/view/146
Keywords
efficacy safety depression genetic variation drug response nucleotide polymorphism heart rate wearable devices dorsalis pedis smart shoes factores de riesgo; riesgo preconcepcional; edad fértilfactores de riesgo riesgo preconcepcional edad fértil

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.